HUTCHMED and AstraZeneca Submit US NDA for ORPATHYS Plus TAGRISSO
HONG KONG, SHANGHAI and FLORHAM PARK, N.J. — September 29, 2026 HUTCHMED (China) Limited announced that AstraZeneca has submitted...
non-small cell lung cancer
Advertisement
Takeda Highlights Arcotatug and TAK-928 at ESMO 2026
OSAKA, Japan and CAMBRIDGE, Mass. — September 22, 2026 Takeda announced that new data from its oncology pipeline and...
Iterion Therapeutics Reports Positive Tegavivint Phase 1b Data
Houston, Texas, U.S., September 22, 2026 Iterion Therapeutics has announced promising results from a Phase 1b clinical study evaluating...
MAIA Advances Phase 3 Ateganosine Trial in Advanced NSCLC
CHICAGO — September 22, 2026 MAIA Biotechnology announced that enrollment has reached 65 patients in the pivotal Phase 3...
OSE to Present Phase 2 Tedopi Data in Metastatic NSCLC
NANTES, France — September 23, 2026 OSE Immunotherapeutics announced that topline results from the Combi-TED Phase 2 trial of...
Advertisements
Natera Reports Largest Lung Cancer MRD Study for Signatera
AUSTIN, Texas — September 18, 2026 Natera announced new data from the IASLC 2026 World Conference on Lung Cancer...
Insilico Medicine Advances AI-Designed BTK Cancer Drugs
Abu Dhabi, UAE, September 17, 2026 Insilico Medicine has announced a new milestone from its UAE-based AI drug discovery...
DarioHealth Expands AI Care to 1.5 Million Lives
New York, New York, September 17, 2026 DarioHealth Corp. has announced a new contract with one of New Jersey’s...
Nuvation Bio IBTROZI Label Updated With Long-Term Data
New York, New York, September 17, 2026 Nuvation Bio Inc. has announced that the U.S. Food and Drug Administration...
MAIA Biotechnology Doses First U.S. Patient in THIO-101
CHICAGO — September 16, 2026 MAIA Biotechnology, Inc. announced that the first U.S. patient has been dosed in the...
Advertisement
